ALK | Allergy solutions for life
ALK

Pioneering in the field of respiratory allergies for more than a century, we've embarked on a mission to help more people, with more solutions, more efficiently.

News

  • Post date
    09/08/2025
    Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray
  • Post date
    09/04/2025
    ALK expands the Executive Leadership Team to include key commercial regions
  • Post date
    08/21/2025
    Six-month interim report (Q2) 2025 (unaudited)
  • Post date
    08/14/2025
    Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025
  • Post date
    08/12/2025
    ALK upgrades its full-year revenue outlook
  • Post date
    07/21/2025
    ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system
  • Post date
    07/18/2025
    EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
  • Post date
    06/26/2025
    First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany
  • Post date
    06/16/2025
    ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025
ALK corporate strategy 2024-2028
As the pioneers of allergy solutions, we are stepping into the next 100 years with a mission to help more people, with more solutions, more efficiently. We call it Allergy+.
100 years of pioneering allergy solutions
A new book has been written about ALK’s fascinating development in the field of allergy
The hunt for a vaccine – a podcast in five episodes
A fascinating story about ALK and the company’s 100 years of hunting allergy vaccines have been turned into a captivating podcast.
Image
ALK homepage video thumbnail
We are the pioneers of allergy solutions

For more than a 100 years, ALK has been at the forefront of allergy research and treatment. We're on a mission to help even more people globally, reaching 5 million people a year by 2030.

ALK in brief

Avatar

Allergy solutions

Allergy is caused by an overreaction of the body’s immune system to substances that in most cases would otherwise be harmless. Learn about the chronic disease, diagnosis, and treatment options.

Avatar

Sustainability

We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.

Avatar

Careers

Become part of a team that is passionate about making a difference for people living with allergy. In our global company, we share expertise and knowledge across boarders and cultures and have a focus on continuous employee development.